Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017–1029.
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, . Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515–1525.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, . ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, . ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Jain S, Keating MJ, . Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923–1930.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, . 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516–2522.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, . Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, . V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Chuang EY, Davis RE, . Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428–1434.
   PubMed Web of Science ®Google Scholar
• Zenz T, Habe S, Denzel T, . Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589–2597.
   PubMed Web of Science ®Google Scholar
• Dicker F, Herholz H, Schnittger S, . The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117–124.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, . The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701–713.
   PubMed Web of Science ®Google Scholar
• Dicker F, Kater AP, Prada CE, . CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006;108:3450–3457.
   PubMed Web of Science ®Google Scholar
• Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438–1449.
   PubMed Web of Science ®Google Scholar
• Strano S, Munarriz E, Rossi M, . Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000;275:29503–29512.
   PubMed Web of Science ®Google Scholar
• Girnita L, Girnita A, Brodin B, . Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 2000;60:5278–5283.
   PubMed Web of Science ®Google Scholar
• Lee YI, Han YJ, Lee SY, . Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249. Mol Cell Endocrinol 2003;203:51–63.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Bishop MR, Copple B, . Oligonucleotide enhanced cytotoxicity of idarubicin for lymphoma cells. Leuk Lymphoma 2001;42:417–427.
   PubMed Web of Science ®Google Scholar
• Bayever E, Haines KM, Iversen PL, . Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 1994;12:223–231.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Iversen PL, Bayever E, . Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996;14:1320–1326.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112: 975–980.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, . Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4070–4078.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, . Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117:3016–3024.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Hornik K. R FAQ. 2011. Available from: http://CRAN.R-project.org/doc/FAQ/R-FAQ.html
   Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, . Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, . Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Kuppers R, . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10:37–50.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Kontoyiannis D, . Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755–1762.
   PubMed Web of Science ®Google Scholar